CIK 0001326190
- Non-accelerated filer
- Smaller reporting company
Altimmune, Inc.
Sign in to watch- Ticker
- ALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 202726770
- Phone
- +1 862-457-1450
- Business address
- 350 MOUNT KEMBLE AVENUE, SUITE 1001, MORRISTOWN, NJ, 07960
- Former names
- PHARMATHENE, INC, HEALTHCARE ACQUISITION CORP
- Open-market buys, last 90 days
- $82,244
- in 3 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$82,244. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-08-21 | Truffle Capital S.A.S. 10% owner | Purchase · Series B Convertible Preferred Stock | +204.89 | $940.00 | $193K | 204.89 |
| 2017-08-21 | Truffle Capital S.A.S. 10% owner | Purchase · Warrant | +30,696 | 30,696 | ||
| 2017-08-21 | Truffle Capital S.A.S. 10% owner | Purchase · Warrant | +40,927 | 40,927 | ||
| 2017-08-21 | Truffle Capital S.A.S. 10% owner | Purchase · Warrant | +30,696 | 30,696 | ||
| 2017-08-21 | Novartis Bioventures Ltd 10% owner | Purchase · Series B Convertible Preferred Stock | +3,104.45 | $940.00 | $2.9M | 3,104.45 |
| 2017-08-21 | Novartis Bioventures Ltd 10% owner | Purchase · Warrant | +465,086 | 465,086 | ||
| 2017-08-16 | Enright William President and CEO | Option exercise | +71,644 | $0.08 | $6K | 89,431 |
| 2017-08-16 | Enright William President and CEO | Option exercise | +91,733 | $0.08 | $7K | 181,164 |
| 2017-08-16 | Enright William President and CEO | Option exercise · Stock Options (option to buy) | −71,644 | 0 | ||
| 2017-08-16 | Enright William President and CEO | Option exercise · Stock Options (option to buy) | −91,733 | 0 | ||
| 2017-06-06 | Roberts M Scot Chief Scientific Officer | Purchase | +449 | $4.42 | $2K | 449 |
| 2017-06-06 | Tasker Sybil Chief Medical Officer | Grant or award · Stock Options (option to buy) | +40,000 | 40,000 | ||
| 2017-06-02 | GILL JOHN Director | Purchase | +1,000 | $4.34 | $4K | 83,224 |
| 2017-05-04 | Drutz David Director | Grant or award · Stock Options (option to buy) | +139 | 139 | ||
| 2017-05-04 | Drutz David Director | Grant or award · Stock Options (option to buy) | +139 | 139 | ||
| 2017-05-04 | Tasker Sybil See Remarks | Grant or award · Stock Options (option to buy) | +48,691 | 48,691 | ||
| 2017-05-04 | Schafer Klaus Director | Grant or award | +5,998 | 5,998 | ||
| 2017-05-04 | Schafer Klaus Director | Grant or award · Stock Option (option to buy) | +4,775 | 4,775 | ||
| 2017-05-04 | Schafer Klaus Director | Grant or award · Stock Option (option to buy) | +1,791 | 1,791 | ||
| 2017-05-04 | Schafer Klaus Director | Grant or award · Stock Option (option to buy) | +1,791 | 1,791 |
Page 31 of 43 · 845 trades